Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Efavirenz + Emtricitabine + Tenofovir disoproxil
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
7 branded products available
MHRA licensed products
View all licensed products for Efavirenz + Emtricitabine + Tenofovir disoproxil on the MHRA register
Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets
Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets
Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets
Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets
Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 12 · Randomised trials: 27 · 2006–2026
Showing the 50 most relevant studies, sorted by most relevant.
François Venter, Simiso Sokhela, Bryony Simmons, et al.
The Lancet HIV, 2020
- Emtricitabine
- Tenofovir
- Duration of Therapy
Steve Kanters, Marco Vitória, Michael J. Zoratti, et al.
EClinicalMedicine, 2020
P. Sax, E. Dejesus, A. Mills, et al.
Lancet, 2012
- Emtricitabine
- Tenofovir
- Cobicistat
Jean‐Michel Molina, Pedro Cahn, Beatriz Grinsztejn, et al.
The Lancet, 2011
- Emtricitabine
- Rilpivirine
- Tenofovir
Calvin Cohen, Jaime Andrade‐Villanueva, Bonaventura Clotet, et al.
The Lancet, 2011
- Emtricitabine
- Rilpivirine
- Tenofovir
Leigh Peterson, Doug Taylor, Ronald E. Roddy, et al.
PLoS Clinical Trials, 2007
Shahin Lockman, Sean S. Brummel, Lauren Ziemba, et al.
The Lancet, 2021
- Emtricitabine
- Tenofovir
- Dolutegravir
L. Wang, Athena P. Kourtis, Sascha Ellington, et al.
Clinical Infectious Diseases, 2013
- Tenofovir
- Adenine
- Pregnancy Complications, Infectious
Kathleen Mulligan, David V. Glidden, Peter L. Anderson, et al.
Clinical Infectious Diseases, 2015
- Emtricitabine
- Tenofovir
- Cytoplasm
Ghosn J, Chow J, Gandhi M, et al.
2025
- HIV Infections
- Adenine
- Anti-HIV Agents
BackgroundTreatment guidelines recommend rapid antiretroviral therapy (ART) initiation among eligible people with HIV to improve treatment outcomes and reduce HIV transmission. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), an integrase strand transfer inhibitor-based single-tablet regimen, is recommended for rapid start in US and European guidelines. This systematic literature review synthesized evidence on the efficacy, safety and effect on patient-reported outcomes (PROs) of B/F/TAF rapid start among newly diagnosed people with HIV.MethodsMEDLINE, Embase, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials databases were searched in January 2024, supplemented by searches of conference proceedings and clinical trial records. English-language interventional studies of B/F/TAF rapid start among ART-naïve people with HIV reporting efficacy, safety or PROs were eligible. Study quality was assessed using York Centre for Reviews and Dissemination or Risk Of Bias In Non-randomized Studies of Interventions checklists. Results were synthesized narratively.ResultsAcross eight included studies, 745 people with HIV received B/F/TAF rapid start, 171 received rapid start comparators and 255 received non-rapid start comparators. At Weeks 24 and 48, 80%-94% and 74%-96% of people with HIV treated with B/F/TAF rapid start achieved viral load ConclusionsB/F/TAF rapid start was efficacious, safe and associated with high engagement in care and improved PROs.
Abstract licence: CC BY-NC
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.